Evidence map›Paper›PMID 29940370›Full record

ArticleActa biomaterialia2018

α-Galactosylceramide and peptide-based nano-vaccine synergistically induced a strong tumor suppressive effect in melanoma.

Vanessa Sainz, Liane I F Moura, Carina Peres, Ana I Matos, Ana S Viana, Angela M Wagner, Julia E Vela Ramirez, Teresa S Barata, Manuela Gaspar, Steve Brocchini and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta biomaterialia, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Fabrication of subunit nanovaccines by physical interaction.Science China. Technological sciences · 2022
    Review
  12. Review
  13. Review
  14. Harnessing NKT cells for vaccination.Oxford open immunology · 2021
    Review
  15. CpG-Based Nanovaccines for Cancer Immunotherapy.International journal of nanomedicine · 2021
    Review
  16. Review
  17. Review
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 4 countries.

Vanessa SainzResearch Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Av. Professor Gama Pinto, Lisbon 1649-003, Portugal; Department of Pharmaceutics, The School of Pharmacy, University College London, 29/39 Brunswick Square, London WC1N 1AX, UK; School of Life and Medical Sciences, University of Hertfordshire, College Lane, Hatfield AL10 9AB, UK.
Liane I F MouraResearch Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Av. Professor Gama Pinto, Lisbon 1649-003, Portugal; School of Life and Medical Sciences, University of Hertfordshire, College Lane, Hatfield AL10 9AB, UK.
Carina PeresResearch Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Av. Professor Gama Pinto, Lisbon 1649-003, Portugal.
Ana I MatosResearch Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Av. Professor Gama Pinto, Lisbon 1649-003, Portugal.
Ana S VianaChemistry and Biochemistry Center, Sciences Faculty, Universidade de Lisboa, 1749-016 Lisbon, Portugal.
Angela M WagnerMcKetta Department of Chemical Engineering, The University of Texas at Austin, Austin, TX 78712, USA; Institute for Biomaterials, Drug Delivery, and Regenerative Medicine, The University of Texas at Austin, Austin, TX 78712, USA.
Julia E Vela RamirezDepartment of Biomedical Engineering, The University of Texas at Austin, Austin, TX 78712, USA; Institute for Biomaterials, Drug Delivery, and Regenerative Medicine, The University of Texas at Austin, Austin, TX 78712, USA.
Teresa S BarataDepartment of Pharmaceutics, The School of Pharmacy, University College London, 29/39 Brunswick Square, London WC1N 1AX, UK.
Manuela GasparResearch Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Av. Professor Gama Pinto, Lisbon 1649-003, Portugal.
Steve BrocchiniDepartment of Pharmaceutics, The School of Pharmacy, University College London, 29/39 Brunswick Square, London WC1N 1AX, UK.
Mire ZlohSchool of Life and Medical Sciences, University of Hertfordshire, College Lane, Hatfield AL10 9AB, UK.
Nicholas A PeppasMcKetta Department of Chemical Engineering, The University of Texas at Austin, Austin, TX 78712, USA; Department of Biomedical Engineering, The University of Texas at Austin, Austin, TX 78712, USA; Institute for Biomaterials, Drug Delivery, and Regenerative Medicine, The University of Texas at Austin, Austin, TX 78712, USA; Division of Pharmaceutics, College of Pharmacy, The University of Texas at Austin, Austin, TX 78712, USA; Department of Pediatrics, Dell Medical School, The University of Texas at Austin, Austin, TX 78712, USA.
Ronit Satchi-FainaroDepartment of Physiology and Pharmacology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel; Sagol School of Neuroscience, Tel Aviv University, Tel Aviv 69978, Israel.
Helena F FlorindoResearch Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Av. Professor Gama Pinto, Lisbon 1649-003, Portugal. Electronic address: hflorindo@ff.ul.pt.
University of Lisbon · PTThe University of Texas at Austin · USUniversity College London · GBUniversity of Hertfordshire · GBTel Aviv University · IL

Funding

pH Sensitive Complex Hydrogels for Protein Drug ReleaseR01EB000246 · NIBIB · UNIVERSITY OF TEXAS AUSTIN · PI LOWMAN, ANTHONY M, PEPPAS, NICHOLAS A · 2002 to 2014
$3.8M
Sensor arrays based on molecularly imprinted polymers for diagnosis of Sjogren's syndromeR01EB022025 · NIBIB · UNIVERSITY OF TEXAS AT AUSTIN · PI ANSLYN, ERIC V., PEPPAS, NICHOLAS A · 2016 to 2019
$1.5M
PH-SENSITIVE HYDROGELS FOR DRUG RELEASER01GM043337 · NIGMS · PURDUE UNIVERSITY WEST LAFAYETTE · PI PEPPAS, NICHOLAS A · 1990 to 2001
$590k
NIBIB NIH HHS R01 EB000246NIBIB NIH HHS R01 EB022025NIGMS NIH HHS R01 GM043337
6 · The paper itself

Abstract

α-Galactosylceramide (GalCer) is a glycolipid widely known as an activator of Natural killer T (NKT) cells, constituting a promising adjuvant against cancer, including melanoma. However, limited clinical outcomes have been obtained so far. This study evaluated the synergy between GalCer and major histocompatibility complex (MHC) class I and MHC class II melanoma-associated peptide antigens and the Toll-Like Receptor (TLR) ligands CpG and monophosphoryl lipid A (MPLA), which we intended to maximize following their co-delivery by a nanoparticle (NP). This is expected to improve GalCer capture by dendritic cells (DCs) and subsequent presentation to NKT cells, simultaneously inducing an anti-tumor specific T-cell mediated immunity. The combination of GalCer with melanoma peptides and TLR ligands successfully restrained tumor growth. The tumor volume in these animals was 5-fold lower than the ones presented by mice immunized with NPs not containing GalCer. However, tumor growth was controlled at similar levels by GalCer entrapped or in its soluble form, when mixed with antigens and TLR ligands. Those two groups showed an improved infiltration of T lymphocytes into the tumor, but only GalCer-loaded nano-vaccine induced a prominent and enhanced infiltration of NKT and NK cells. In addition, splenocytes of these animals secreted levels of IFN-γ and IL-4 at least 1.5-fold and 2-fold higher, respectively, than those treated with the mixture of antigens and adjuvants in solution. Overall, the combined delivery of the NKT agonist with TLR ligands and melanoma antigens via this multivalent nano-vaccine displayed a synergistic anti-tumor immune-mediated efficacy in B16F10 melanoma mouse model. STATEMENT OF SIGNIFICANCE: Combination of α-galactosylceramide (GalCer), a Natural Killer T (NKT) cell agonist, with melanoma-associated antigens presented by MHC class I (Melan-A:26) and MHC class II (gp100:44) molecules, and Toll-like Receptor (TLR) ligands (MPLA and CpG), within nanoparticle matrix induced a prominent anti-tumor immune response able to restrict melanoma growth. An enhanced infiltration of NKT and NK cells into tumor site was only achieved when the combination GalCer, antigens and TLR ligands were co-delivered by the nanovaccine.

Indexed as

Cancer VaccinesGalactosylceramidesNanoparticlesPeptidesAnimalsCell Line, TumorDendritic CellsImmunity, CellularKiller Cells, NaturalMaleMelanoma, ExperimentalMiceMice, Inbred C57BLT-LymphocytesToll-Like Receptorsalpha-galactosylceramideCancer VaccinesGalactosylceramidesPeptidesToll-Like ReceptorsMelanomaNanoparticlesNatural killer T cellsToll-like receptor ligandsα-Galactosylceramide

Identifiers

PMID29940370
PMCPMC6124890
OpenAlexW2810530668

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.